Physician profile
Rene Koppel
NPI 1861459547
$6,285.54
in general payments reported to CMS, 2019-2025
35 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $778 · 2021: $624 · 2022: $837 · 2023: $1,091 · 2024: $1,038 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,194 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,194.35 |
| Education | $161.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $858.68 | 2019-2025 | |
| Abbvie INC. | $819.19 | 2019-2025 | |
| Janssen Biotech, INC. | $646.32 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $601.56 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $377.09 | 2020-2025 | Ilumya |
| Mayne Pharma Commercial LLC | $307.92 | 2019-2024 | |
| Pfizer INC. | $264.89 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $263.59 | 2020-2025 | Dupixent, Libtayo |
| Ucb, INC. | $255.44 | 2020-2025 | Bimzelx |
| Amgen INC. | $225.88 | 2019-2025 | Otezla |
| Leo Pharma INC. | $223.22 | 2019-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $217.09 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $200.84 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $145.62 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $136.62 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $120.91 | 2020-2025 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $100.45 | 2023-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.10 | 2023-2024 | Spevigo |
| Revance Therapeutics, INC. | $62.50 | 2024 | Daxxify |
| Allergan, INC. | $53.85 | 2021-2022 | |
| Incyte Corporation | $46.06 | 2023-2024 | Opzelura |
| Medimetriks Pharmaceuticals, INC. | $34.40 | 2020-2025 | Neo-Synalar |
| Celgene Corporation | $33.99 | 2019 | |
| Hill Dermaceuticals, INC. | $22.75 | 2021-2023 | Tolak |
| Mallinckrodt Hospital Products INC. | $22.07 | 2024 | Acthar |
| Sanofi-Aventis U.S. LLC | $22.07 | 2020 | |
| Journey Medical Corporation | $21.71 | 2019 | |
| Dermira, INC. | $20.29 | 2020 | |
| Genentech USA, INC. | $18.28 | 2019 | |
| Verrica Pharmaceuticals INC. | $17.87 | 2023 | Ycanth |
| Biofrontera INC. | $17.85 | 2020 | |
| Cipher Pharmaceuticals US LLC | $17.50 | 2025 | Natroba, Spinosad |
| Galderma Laboratories, L.P. | $16.27 | 2020 | |
| Pierre Fabre Pharmaceuticals, INC. | $8.72 | 2019 | |
| Organon LLC | $4.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Koppel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.